PyInvesting

Market research

APLLTD.NSE Alembic Pharmaceuticals Limited

NSE INR Healthcare

Latest close

1,040.95 —

As of Nov 20, 2026

Test a moving-average rule with historical data.

Market facts

Market cap
200B
P/E ratio
24.8
Analyst target
1029.7
Dividend yield
0.0%
Beta
0.34

Community

Investor discussion

1 comment

Admin profile picture
Admin

Apr 1, 2021

Alembic Pharmaceuticals Limited is currently in a long term uptrend where the price is trading 0.6% above its 200 day moving average.

From a valuation standpoint, the stock is 24.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.6.

Alembic Pharmaceuticals Limited's total revenue rose by 8.7% to $13B since the same quarter in the previous year.

Its net income has increased by 24.9% to $3B since the same quarter in the previous year.

Finally, its free cash flow grew by 582.7% to $9B since the same quarter in the previous year.

Based on the above factors, Alembic Pharmaceuticals Limited gets an overall score of 5/5.